Novo's Victoza targets the 'niche obese'
This article was originally published in Scrip
Executive Summary
Novo Nordisk is set to file its hugely successful diabetes drug, GLP-1 agonist Victoza (liraglutide), for the additional indication of obesity in the coming weeks. However, its CSO Mads Krogsgaard Thomsen tells Scrip that his company is not suggesting that every obese person take the medication.